ACIR features Immunetune’s presentation at CIMT Annual Meeting 2022

May 18, 2022

Accelerating Cancer Immunotherapy Research (ACIR) has featured Immunetune’s presentation during the Cancer Immunotherapy (CIMT) Annual Meeting 2022 held May 10-12 in Mainz, Germany. At CIMT, our CSO Jeroen van Bergen presented new preclinical results on our neoantigen cancer vaccine in combination with checkpoint inhibitors.

ACIR’s mission is to accelerate the advancement of cancer immunotherapy by providing, free-of-charge and readily accessible on the internet, a weekly synopsis of the key advances in this fast moving and multifaceted field.